New combo therapy shows promise for avoiding colostomy in Ultra-Low rectal cancer
NCT ID NCT05215379
First seen Jan 05, 2026 · Last updated Jun 09, 2026 · Updated 27 times
Summary
This study tested whether adding immunotherapy to standard chemoradiation before surgery could help people with a certain type of ultra-low rectal cancer (MSS) avoid permanent colostomy. About 200 patients who wanted to save their anus took part. The main goal was to see how many achieved a complete clinical response, meaning no cancer could be found after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Colorectal Surgery in Changhai Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.